In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Vivani Medical (VANI – Research Report), with a price target of $4.00. The company’s shares opened today at $1.09.
According to TipRanks, Rahman is an analyst with an average return of -9.6% and a 33.57% success rate. Rahman covers the Healthcare sector, focusing on stocks such as PainReform, Vertex Pharmaceuticals, and Viking Therapeutics.
Currently, the analyst consensus on Vivani Medical is a Moderate Buy with an average price target of $4.00.
See today’s best-performing stocks on TipRanks >>
Based on Vivani Medical’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.08 million. In comparison, last year the company had a GAAP net loss of $2.21 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VANI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Read More on VANI:
